Myriad Genetics, Inc. (NASDAQ:MYGN) had its target price increased by investment analysts at Deutsche Bank AG from $28.00 to $30.00 in a research note issued on Wednesday. The firm currently has a “hold” rating on the stock. Deutsche Bank AG’s price objective indicates a potential downside of 4.91% from the stock’s current price.

MYGN has been the topic of a number of other research reports. Morgan Stanley reissued an “underweight” rating and issued a $24.00 target price (up previously from $17.00) on shares of Myriad Genetics in a research report on Friday, October 6th. Zacks Investment Research raised Myriad Genetics from a “hold” rating to a “strong-buy” rating and set a $42.00 target price on the stock in a research report on Tuesday, October 17th. BidaskClub lowered Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, August 3rd. Stephens reissued an “overweight” rating and issued a $40.00 target price (up previously from $36.00) on shares of Myriad Genetics in a research report on Friday, September 22nd. Finally, Leerink Swann reissued a “market perform” rating and issued a $31.00 target price on shares of Myriad Genetics in a research report on Monday, October 2nd. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $28.10.

Myriad Genetics (MYGN) traded up $0.46 during midday trading on Wednesday, hitting $31.55. The stock had a trading volume of 670,913 shares, compared to its average volume of 1,060,000. The firm has a market capitalization of $2,170.00, a price-to-earnings ratio of 27.63, a P/E/G ratio of 1.94 and a beta of 0.24. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.26 and a current ratio of 2.34. Myriad Genetics has a 52 week low of $15.15 and a 52 week high of $37.30.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 EPS for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.05. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The company had revenue of $190.20 million for the quarter, compared to analyst estimates of $183.52 million. During the same quarter last year, the firm posted $0.23 earnings per share. Myriad Genetics’s revenue was up 7.2% compared to the same quarter last year. analysts anticipate that Myriad Genetics will post 1.03 EPS for the current fiscal year.

WARNING: “Myriad Genetics, Inc. (MYGN) PT Raised to $30.00” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/11/10/myriad-genetics-inc-mygn-pt-raised-to-30-00.html.

In other Myriad Genetics news, Director John T. Henderson sold 30,000 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $30.30, for a total value of $909,000.00. Following the completion of the transaction, the director now directly owns 52,524 shares in the company, valued at $1,591,477.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 6.70% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of the business. CS Mckee LP grew its stake in Myriad Genetics by 0.3% in the second quarter. CS Mckee LP now owns 30,000 shares of the company’s stock valued at $775,000 after purchasing an additional 100 shares in the last quarter. Municipal Employees Retirement System of Michigan grew its stake in Myriad Genetics by 3.1% in the second quarter. Municipal Employees Retirement System of Michigan now owns 16,080 shares of the company’s stock valued at $416,000 after purchasing an additional 490 shares in the last quarter. Aperio Group LLC grew its stake in Myriad Genetics by 4.6% in the second quarter. Aperio Group LLC now owns 12,129 shares of the company’s stock valued at $313,000 after purchasing an additional 534 shares in the last quarter. LeJeune Puetz Investment Counsel LLC grew its stake in Myriad Genetics by 3.3% in the second quarter. LeJeune Puetz Investment Counsel LLC now owns 31,025 shares of the company’s stock valued at $802,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Teachers Advisors LLC boosted its stake in shares of Myriad Genetics by 1.1% during the 1st quarter. Teachers Advisors LLC now owns 116,924 shares of the company’s stock worth $2,245,000 after acquiring an additional 1,287 shares during the period.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Stock Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related stocks with our FREE daily email newsletter.